Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression.
In a double-blind, placebo-controlled study the authors found that fluoxetine, a potent and selective inhibitor of serotonin reuptake, was an effective antidepressant in moderately depressed, ambulatory outpatients. Typical adverse effects reported by patients treated with fluoxetine included agitation, nausea, fatigue, and insomnia. Compared to imipramine, fluoxetine was associated with fewer complaints of dry mouth, constipation, and dizziness.
Byerley
W F
WF
Department of Psychiatry, University of Utah Medical Center, Salt Lake City 84132.
Reimherr
F W
FW
Wood
D R
DR
Grosser
B I
BI
D000328:Adult; D000553:Ambulatory Care; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005473:Fluoxetine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007099:Imipramine / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011437:Propylamines / Q000627:therapeutic use*; D011897:Random Allocation
D011437:Propylamines; D005473:Fluoxetine; D007099:Imipramine